Quick Answer
BioXcel Therapeutics, Inc. reported Operating Income Loss of -$50.46 million for the year ending 2025.
- BioXcel Therapeutics, Inc. showed an increase of +25.0% in Operating Income Loss from 2024 to 2025.
- This data is from BioXcel Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 27, 2026.
- XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2017: -$529.0 thousand | Q2 2017: -$565.0 thousand | Q3 2017: -$917.0 thousand | Q1 2018: -$4.29 million | Q2 2018: -$3.24 million | Q3 2018: -$5.12 million | Q1 2019: -$7.42 million | Q2 2019: -$8.64 million | Q3 2019: -$9.13 million | Q1 2020: -$15.00 million | Q2 2020: -$21.44 million | Q3 2020: -$24.77 million | Q1 2021: -$26.38 million | Q2 2021: -$27.61 million | Q3 2021: -$26.81 million | Q1 2022: -$31.48 million | Q2 2022: -$36.29 million | Q3 2022: -$38.99 million | Q1 2023: -$51.20 million | Q2 2023: -$52.41 million | Q3 2023: -$48.30 million | Q1 2024: -$24.16 million | Q2 2024: -$17.30 million | Q3 2024: -$15.29 million | Q1 2025: -$10.10 million | Q2 2025: -$15.85 million | Q3 2025: -$14.23 million.
- Over the full 9 years of available data (2017 to 2025), BioXcel Therapeutics, Inc.'s Operating Income Loss has declined by 1,012.2%.
- Historical annual values: Fiscal year 2025: -$50.46 million | Fiscal year 2024: -$67.25 million | Fiscal year 2023: -$171.78 million | Fiscal year 2022: -$159.65 million | Fiscal year 2021: -$106.94 million | Fiscal year 2020: -$82.30 million | Fiscal year 2019: -$33.60 million | Fiscal year 2018: -$19.96 million | Fiscal year 2017: -$4.54 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: